Colorectal Cancer | Clinical

January 23, 2022

The observational GALAXY study has shown that using a ctDNA assay may help identify which patients with colorectal cancer have the potential to derive benefit from adjuvant chemotherapy.

January 23, 2022

CheckMate 9X8 trial results indicate a progression-free survival improvement with nivolumab that was not statistically significant.

January 22, 2022

Promising study results support continued research of T-DXd in patients with HER2-positive mCRC while the risk of potential ILD/pneumonitis requires monitoring.

January 22, 2022

Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.

January 22, 2022

In a phase 1/2 study demonstrated that the combination of encorafenib, cetuximab, and nivolumab was well tolerated and led to responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

January 22, 2022

Results from a large trial evaluating the combination of pembrolizumab and regorafenib showed durable results for patients with microsatellite stable colorectal cancer.

January 22, 2022

Treatment with a triplet combination of pembrolizumab, binimetinib and bevacizumab was associated with an observed clinical benefit in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

January 22, 2022

Phase 1b/2 data for the combination of onvansertib with FOLFIR I and bevacizumab appear promising for paints with KRAS-mutant metastatic colorectal cancer.

January 11, 2022

During a Targeted Oncology Case-Based Roundtable event, Alan Venook, MD, professor of medicine at the University of California, San Francisco, discussed the data related to regorafenib therapy for relapsed/refractory metastatic colorectal cancer.

January 05, 2022

Sotorasib produced an objective response rate of 9.7% in patients with colorectal cancer.